The 18F-FDG positron-emission tomography (PET) and contrast-enhanced computerised tomography (CECT) data of all relapsed or refractory HL treated at Gustave Roussy, Villejuif, France, from 2013 to 2015 were retrospectively reviewed according to the International Harmonisation Project Cheson 2014 criteria and the LYmphoma Response to Immunomodulatory therapy Criteria (LYRIC).
Predictions of outcome after first-line treatment for DLBCL were surprisingly good when left to the unsupervised, subjective judgment of experienced readers of lymphoma 18F-FDG-PET/CT.
However, several pitfalls may occur during or after treatment, because of the nonspecificity of F-FDG for lymphoma disease and treatment as immunotherapy, thus possibly induces misinterpretation and wrong treatment decision.
Interim and posttreatment sequential FDG PET/CT scans revealed a residual splenic mass showing markedly intense FDG uptake suspected of a residual viable lymphoma.
Although <sup>18</sup>F-FDG has proved useful in the management of patients with lymphoma, the specificity of <sup>18</sup>F-FDG uptake has been critically questioned, and is not without flaws.
The impact of early fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography (FDG PET-CT) status on survival after allogeneic transplantation for lymphoma is poorly reported.
Burkitt's lymphoma is a lymphoma with unclear metabolic behavior at 18F-FDG-PET/CT and no validated criteria in treatment evaluation and prediction of outcome exist.
[<sup>18</sup>F]FB-GAcDb immunoPET was further evaluated in a disseminated lymphoma (A20-hCD20) syngeneic for hCD20TM and compared to [<sup>18</sup>F]FDG PET.
F-FDG PET/CT showed hypermetabolic foci in the liver, spleen, and bone marrow, as well as multiple FDG-avid lymph nodes, which were highly suggestive of lymphoma.
FDG PET/CT has optimum negative predictive value compared with BMB in detection of bone marrow infiltrations in pediatric lymphoma with upstaging cases missed with BMB.
Except for SUVmin (<i>p</i>=0.971), the averages of FDG uptake metrics of lymphoma were significantly higher than those of carcinoma (<i>p</i> ≤ 0.001), with the following median values: SUV<sub>mean</sub>, 4.75 versus 2.38 g/ml (<i>P</i> < 0.001); SUV<sub>std</sub>, 2.04 versus 0.88 g/ml (<i>P</i>=0.001); SUV<sub>max</sub>, 10.69 versus 4.76 g/ml (<i>P</i>=0.001); SUV<sub>peak</sub>, 9.15 versus 2.78 g/ml (<i>P</i> < 0.001); TLG, 42.24 versus 9.90 (<i>P</i> < 0.001).
In this case, we aim to highlight this interesting FDG PET/CT imaging finding, which can serve as a clue allowing one to strongly suggest lymphoma as the leading diagnosis.
This was a retrospective study of 238 patients, including 92 with type-2 DM (DM2) and 11 with type-1 DM (DM1), having routine whole body FDG PET/CT.Patients with lymphoma were excluded.